Abstract
Objective To understand COVID-19 vaccine hesitancy.
Methods January 6 through May 31, 2021, 5,121,436 US adults completed an online COVID-19 survey. Weighted data was used to evaluate change in vaccine intent and correlates of May vaccine hesitancy.
Results COVID-19 vaccine hesitancy decreased by one-third from January to May, with relatively large decreases among participants with Black, Pacific Islander or Hispanic race/ethnicity and ≤high school education. In May, independent hesitancy risk factors included younger age, non-Asian race, having a PhD or ≤high school education, living in a rural county, living in a county with higher 2020 Trump support, lack of worry about COVID-19, working outside the home, never intentionally avoiding contact with others, and no past-year flu vaccine. Differences in hesitancy by race/ethnicity varied by age. Almost half of vaccine hesitant respondents reported fear of side effects and not trusting the COVID-19 vaccine; over one-third reported not trusting the government, not needing the vaccine, and waiting to see if safe. Reasons differed by degree of vaccine intent and by race/ethnicity.
Conclusion COVID-19 vaccine hesitancy varied by demographics, geography, beliefs, and behaviors.
Competing Interest Statement
Drs. King, Mejia and Mr. Rubenstein have no conflict of interest to report. Dr. Reinhart received salary support from an unrestricted gift from Facebook.
Funding Statement
This material is based upon work supported by Facebook (unrestricted gift) and a cooperative agreement from the Centers for Disease Control and Prevention (U01IP001121). Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of Facebook or the Centers for Disease Control and Prevention. Facebook was involved in the design and conduct of the study. The CDC provided funding only. Neither Facebook nor the Centers for Disease Control and Prevention had a role in the collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Carnegie Mellon University (CMU) Institutional Review Board approved the survey protocol and instrument.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
mrubinst{at}andrew.cmu.edu
areinhar{at}stat.cmu.edu
rmejia{at}andrew.cmu.edu
Data Availability
Survey microdata is available to researchers under a nondisclosure agreement protecting the confidentiality of responses. Access can be requested at https://cmu-delphi.github.io/delphi-epidata/symptom-survey/.
https://cmu-delphi.github.io/delphi-epidata/symptom-survey/coding.html
